Next-generation sequencing in drug development: target identification and genetically stratified clinical trials.

Next-generation sequencing in drug development: target identification and genetically stratified clinical trials.

Drug Discov Today. 2018 May 11;:

Authors: Torshizi AD, Wang K

Abstract
Next-generation sequencing (NGS) enabled high-throughput analysis of genotype-phenotype relationships on human populations, ushering in a new era of genetics-informed drug development. The year 2017 was remarkable, with the first FDA-approved gene therapy for cancer (Kymriah™) and for inherited diseases (LUXTURNA™), the first multiplex NGS panel for companion diagnostics (MSK-IMPACT™) and the first drug targeting a genetic signature rather than a disease (Keytruda®). We envision that population-scale NGS with paired electronic health records (EHRs) will become a routine measure in the drug development process for the identification of novel drug targets, and that genetically stratified clinical trials could be widely adopted to improve power in precision-medicine-guided drug development.

PMID: 29758342 [PubMed – as supplied by publisher]

Be the first to comment

Leave a Reply

Your email address will not be published.


*